---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-182222"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T11:52:43.603649+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adaptive and Genentech terminate cell therapy collaboration; $33.7M non-cash revenue in H2 2025

## Summary
- Strategic Collaboration and License Agreement with Genentech terminated Aug 13, 2025; effective Feb 9, 2026.
- Adaptive expects $33.7M non-cash revenue in H2 2025 from remaining amortization of cash consideration.
- Company released from exclusivity obligations in oncology cell therapies.
- Ongoing Immune Medicine programs: digital TCR-antigen models, T-cell depletion in autoimmunity, FY2025 cash burn target $25-30M.

## SEC filing metadata
- accession: 0001193125-25-182222
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000119312525182222/0001193125-25-182222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000119312525182222/d59058d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-182222
- JSON: https://secwatch.observer/filing/0001193125-25-182222.json
- Plain text: https://secwatch.observer/filing/0001193125-25-182222.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.